BDTX - Black Diamond Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
BDTX price evolution
BDTX
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $33.63 | $26.24 | $57.04 | |
| Short term investments | $90.16 | $89.78 | $75.18 | |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $115.54 | $126.75 | $118.81 | $134.03 |
| Long term investments | ||||
| Property, plant & equipment | $21.24 | $22.07 | $22.9 | $23.71 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $23.23 | $23.71 | $24.53 | |
| Total investments | $90.16 | $89.78 | $75.18 | |
| Total assets | $137.9 | $149.99 | $142.52 | $158.57 |
| Current liabilities | ||||
| Accounts payable | $1.97 | $0.76 | $1.18 | $2.32 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $20.8 | $18.44 | $16.85 | $19.65 |
| Long term debt | $20.53 | $21.36 | $22.18 | |
| Total noncurrent liabilities | $20.53 | $21.36 | $22.18 | |
| Total debt | $20.53 | $21.36 | $22.18 | |
| Total liabilities | $40.47 | $38.97 | $38.22 | $41.83 |
| Shareholders' equity | ||||
| Retained earnings | -$471.12 | -$455.56 | -$435.66 | -$417.43 |
| Other shareholder equity | $0.11 | -$0.12 | -$0.1 | -$0.03 |
| Total shareholder equity | $111.02 | $104.31 | $116.74 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $57.04 | $35.48 | $67.02 | $35.83 |
| Short term investments | $75.18 | $88.49 | $143.99 | $280.46 |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $134.03 | $127.71 | $215.7 | $319.55 |
| Long term investments | ||||
| Property, plant & equipment | $23.71 | $27.38 | $30.74 | $8.79 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $24.53 | $28.55 | $31.98 | $10.12 |
| Total investments | $75.18 | $88.49 | $143.99 | $280.46 |
| Total assets | $158.57 | $156.25 | $247.68 | $329.67 |
| Current liabilities | ||||
| Accounts payable | $2.32 | $1.88 | $4.11 | $2.54 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $19.65 | $15.26 | $23.64 | $14.22 |
| Long term debt | $22.18 | $25.3 | $28.14 | $7.69 |
| Total noncurrent liabilities | $22.18 | $25.3 | $28.14 | $7.69 |
| Total debt | $22.18 | $25.3 | $28.14 | $7.69 |
| Total liabilities | $41.83 | $40.56 | $51.78 | $21.91 |
| Shareholders' equity | ||||
| Retained earnings | -$417.43 | -$334.99 | -$243.82 | -$118.22 |
| Other shareholder equity | -$0.03 | -$1.82 | -$0.41 | $0.61 |
| Total shareholder equity | $116.74 | $115.69 | $195.9 | $307.76 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $12.56 | $13.54 | $15.29 | |
| Selling, general & administrative | $9.57 | $6.7 | $5.57 | |
| Total operating expenses | $18.13 | $22.13 | $20.25 | $20.86 |
| Operating income | -$22.13 | -$20.25 | -$20.86 | |
| Income from continuing operations | ||||
| EBIT | -$19.91 | -$18.23 | -$19.41 | |
| Income tax expense | ||||
| Interest expense | $0.52 | |||
| Net income | ||||
| Net income | -$15.56 | -$19.91 | -$18.23 | -$19.41 |
| Income (for common shares) | -$19.91 | -$18.23 | -$19.41 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $59.35 | $64.44 | $96.83 | $48.21 |
| Selling, general & administrative | $27.11 | $28.39 | $30.04 | $21.36 |
| Total operating expenses | $86.46 | $92.83 | $126.87 | $69.57 |
| Operating income | -$86.46 | -$92.83 | -$126.87 | -$69.57 |
| Income from continuing operations | ||||
| EBIT | -$82.44 | -$91.17 | -$125.6 | -$67.25 |
| Income tax expense | ||||
| Interest expense | $0 | |||
| Net income | ||||
| Net income | -$82.44 | -$91.17 | -$125.6 | -$67.25 |
| Income (for common shares) | -$82.44 | -$91.17 | -$125.6 | -$67.25 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$19.91 | -$18.23 | -$19.41 | |
| Operating activities | ||||
| Depreciation | $0.09 | $0.09 | $0.09 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $5.29 | $1.71 | $1.54 | |
| Total cash flows from operations | -$14.73 | -$21.2 | -$13.96 | |
| Investing activities | ||||
| Capital expenditures | $0.04 | |||
| Investments | $0.7 | -$13.73 | $12.25 | |
| Total cash flows from investing | -$10.8 | $0.74 | -$13.73 | $12.25 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $21.38 | $4.13 | -$0.05 | |
| Net borrowings | ||||
| Total cash flows from financing | $25.26 | $21.38 | $4.13 | -$0.05 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$32.79 | $7.39 | -$30.8 | -$1.75 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$82.44 | -$91.17 | -$125.6 | -$67.25 |
| Operating activities | ||||
| Depreciation | $0.44 | $0.51 | $0.2 | $0.05 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $9.6 | $12.2 | $14.04 | $7.76 |
| Total cash flows from operations | -$66.72 | -$85.08 | -$100.15 | -$52.15 |
| Investing activities | ||||
| Capital expenditures | $0.06 | -$0.18 | -$2.71 | -$0.14 |
| Investments | $16.28 | $53.55 | $133.32 | -$281.55 |
| Total cash flows from investing | $16.35 | $53.37 | $130.61 | -$281.69 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $71.93 | $0.18 | $0.73 | $214.94 |
| Net borrowings | ||||
| Total cash flows from financing | $71.93 | $0.18 | $0.73 | $214.94 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $21.56 | -$31.54 | $31.19 | -$118.89 |
News
Fundamentals
| Market cap | $125.48M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 56.52M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$73.10M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -1.72 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$1.29 |
|---|---|
| ROA | -49.65% |
| ROE | N/A |
| Debt/Equity | 0.36 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 5.55 |
| Quick ratio | N/A |